J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M600060-JLR200 on June 14, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M600060-JLR200v1
47/9/1967    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walton, K. A.
Right arrow Articles by Berliner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walton, K. A.
Right arrow Articles by Berliner, J. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 47, 1967-1974, September 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products

Kimberly A. Walton*, Bogdan G. Gugiu{dagger}, Miracle Thomas§, Robert J. Basseri*, Daniel R. Eliav*, Robert G. Salomon{dagger} and Judith A. Berliner1,*,§

* Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
§ Department of Pathology, University of California, Los Angeles, Los Angeles, CA 90095
{dagger} Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106-7078

Published, JLR Papers in Press, June 14, 2006.

1 To whom correspondence should be addressed. e-mail: jberliner{at}mednet.ucla.edu

Previous studies from our laboratory and others presented evidence that oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphatidylcholine (OxPAPC) and oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphatidylethanolamine can inhibit lipopolysaccharide (LPS)-mediated induction of interleukin-8 (IL-8) in endothelial cells. Using synthetic derivatives of phosphatidylethanolamine, we now demonstrate that phospholipid oxidation products containing {alpha},ß-unsaturated carboxylic acids are the most active inhibitors we examined. 5-Keto-6-octendioic acid ester of 2-phosphatidylcholine (KOdiA-PC) was 500-fold more inhibitory than OxPAPC, being active in the nanomolar range. Our studies in human aortic endothelial cells identify one important mechanism of the inhibitory response as involving the activation of neutral sphingomyelinase. There is evidence that Toll-like receptor-4 and other members of the LPS receptor complex must be colocalized to the caveolar/lipid raft region of the cell, where sphingomyelin is enriched, for effective LPS signaling. Previous work from our laboratory suggested that OxPAPC could disrupt this caveolar fraction. These studies present evidence that OxPAPC activates sphingomyelinase, increasing the levels of 16:0, 22:0, and 24:0 ceramide and that the neutral sphingomyelinase inhibitor GW4869 reduces the inhibitory effect of OxPAPC and KOdiA-PC. We also show that cell-permeant C6 ceramide, like OxPAPC, causes the inhibition of LPS-induced IL-8 synthesis and alters caveolin distribution similar to OxPAPC. Together, these data identify a new pathway by which oxidized phospholipids inhibit LPS action involving the activation of neutral sphingomyelinase, resulting in a change in caveolin distribution. Furthermore, we identify specific oxidized phospholipids responsible for this inhibition.

Supplementary key words lipopolysaccharide • endothelium • ceramide

Abbreviations: A-PE, 1-palmitoyl-2-azelayl-sn-glycero-3-phosphatidylethanolamine; HAEC, human aortic endothelial cell; HDdiA-PE, 9-hydroxy-10-dodecendioic acid ester of lysophosphatidylethanolamine; IL-8, interleukin-8; KDdiA-PE, 9-keto-10-dodecendioic acid ester of lysophosphatidylethanolamine; KOdiA-PC, 5-keto-6-octendioic acid ester of 2-phosphatidylcholine; KOdiA-PE, 5-keto-6-octendioic acid ester of 2-lysophosphatidylethanolamine; LBP, lipopolysaccharide binding protein;; LPS, lipopolysaccharide; MM-LDL, minimally modified low density lipoprotein; ON-PE, 1-palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphatidylethanolamine; OxPAPC, oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphatidylcholine; OxPAPE, oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphatidylethanolamine; POVPC, 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphatidylcholine; sCD14, soluble CD14; TNF-{alpha}, tumor necrosis factor-{alpha}


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Erridge, S. Kennedy, C. M. Spickett, and D. J. Webb
Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4: ROLES FOR CD14, LPS-BINDING PROTEIN, AND MD2 AS TARGETS FOR SPECIFICITY OF INHIBITION
J. Biol. Chem., September 5, 2008; 283(36): 24748 - 24759.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. Sun, T. Fox, G. Adhikary, M. Kester, and E. Pearlman
Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide
J. Leukoc. Biol., June 1, 2008; 83(6): 1512 - 1521.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.